主页 > 生命科学 >
【文摘发布】前列腺特异性抗原倍增时间（PSAT）
前列腺特异性抗原倍增时间（PSAT）的应用现状
Wednesday, 4 June 2008 - Ramirez et al. (2008) reviewed the current status of prostate-specific antigen doubling time (PSADT) as it pertains to the evolution of prostate cancer (PCa), specifically assessing its role in the following four stages: before diagnosis, prior to definitive treatment, following treatment including salvage therapy after recurrence, and lastly, after onset of androgen-insensitive PCa.
Ramirez等（2008）回顾了当前前列腺特异性抗原倍增时间（PSADT）与前列腺癌进展相关的状况，尤其是评估了其在如下四个阶段中的作用：诊断之前，决定性治疗之前，包括复发后挽救治疗的后续处理期，雄激素非敏感性前列腺癌发生之后。
The authors searched PubMed literature for current articles on PSADT using the key words listed for this review and, where possible, selected those with significant levels of evidence that were deemed relevant, seminal, or controversial. The authors summarized the data regarding PSADT as a marker for diagnosis and disease characterization, as well as a predictor of progression, response to treatment, and mortality.
作者采用针对本篇综述所列的关键词方式检索了PubMed数据库中关于PSADT的现有文献，可能情形下，选择那些被认为有关的、原创的或有争议的具有显著证据价值的文献。作者对将PSADT作为疾病诊断标记物及病情特征的数据进行了总结，除此之外，还包括疾病进展预测因子，对治疗有反应以及死亡率的数据。
PSADT may offer an advantage in providing a more dynamic picture of tumor behavior, providing clues regarding the relative aggressiveness of the underlying pathology. Evidence points toward a role for PSADT in the management of PCa, specifically in active surveillance, disease recurrence after treatment, and in androgen-independent PCa. PSADT is an important prognostic factor that may serve as an auxiliary end point for cancer-specific survival; however, optimal cut-off points denoting risk remain debatable.
PSADT在提供更多的肿瘤行为动态图像、考虑存在潜在病理浸润线索方面具有优势。证据表明PSADT在前列腺癌管理，尤其是积极监测、疾病复发后治疗以及雄激素非依赖性前列腺癌的管理中具有价值。PSADT作为一个重要的预后因子，可能在癌症特异性存活中作为一个辅助性终点指标；然而，提示有风险的恰当临界值仍然存在争议。
In conclusion, PCa management requires risk stratification with a combination of variables, PSADT being one of the most reliable predictors. It is now a parameter included in many predictive nomograms and in treatment guidelines for expectant management and salvage therapy.
结论，前列腺癌的管理需要由多个变量组合而成的危险因素分级处理，PSADT则是其中最可靠的预测因素之一。其已经作为一个参数应用于多个预后列线图以及期待治疗与挽救治疗的治疗指南中。
Ramirez, M. L., Nelson, E. C., Devere White, R. W., Lara, P. N., Jr., & Evans, C. P. (2008). Current Applications for Prostate-Specific Antigen Doubling Time. Eur Urol, doi:10.1016/j.eururo.2008.04.003.
Authors: Ramirez et al.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-06 05:11
医学,生命科学网